5VLA
Short PCSK9 delta-P' complex with Fusion2 peptide
Summary for 5VLA
| Entry DOI | 10.2210/pdb5vla/pdb |
| Related | 5VL7 5VLH 5VLK 5VLL 5VLP |
| Descriptor | Proprotein convertase subtilisin/kexin type 9, THR-VAL-PHE-THR-SER-TRP-GLU-GLU-TYR-LEU-ASP-TRP-VAL-MET-PRO-TRP-ASN-LEU-VAL-ARG-ILE-GLY-LEU-LEU, CALCIUM ION, ... (4 entities in total) |
| Functional Keywords | proprotein convertase, subtilisin, hydrolase |
| Biological source | Homo sapiens (Human) More |
| Total number of polymer chains | 2 |
| Total formula weight | 53420.34 |
| Authors | Eigenbrot, C.,Ultsch, M. (deposition date: 2017-04-25, release date: 2017-08-16, Last modification date: 2024-11-13) |
| Primary citation | Zhang, Y.,Ultsch, M.,Skelton, N.J.,Burdick, D.J.,Beresini, M.H.,Li, W.,Kong-Beltran, M.,Peterson, A.,Quinn, J.,Chiu, C.,Wu, Y.,Shia, S.,Moran, P.,Di Lello, P.,Eigenbrot, C.,Kirchhofer, D. Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat. Struct. Mol. Biol., 24:848-856, 2017 Cited by PubMed Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma LDL cholesterol (LDL-c) levels by promoting the degradation of liver LDL receptors (LDLRs). Antibodies that inhibit PCSK9 binding to the EGF(A) domain of the LDLR are effective in lowering LDL-c. However, the discovery of small-molecule therapeutics is hampered by difficulty in targeting the relatively flat EGF(A)-binding site on PCSK9. Here we demonstrate that it is possible to target this site, based on the finding that the PCSK9 P' helix displays conformational flexibility. As a consequence, the vacated N-terminal groove of PCSK9, which is adjacent to the EGF(A)-binding site, is in fact accessible to small peptides. In phage-display experiments, the EGF(A)-mimicking peptide Pep2-8 was used as an anchor peptide for the attachment of an extension peptide library directed toward the groove site. Guided by structural information, we further engineered the identified groove-binding peptides into antagonists, which encroach on the EGF(A)-binding site and inhibit LDLR binding. PubMed: 28825733DOI: 10.1038/nsmb.3453 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.4 Å) |
Structure validation
Download full validation report






